Regeneron Reports Positive Phase 3 Dupixent Data; Gains EU Approval Recommendation

  ()
Regeneron Pharmaceuticals published positive results from two U.S. Phase 3 trials evaluating the safety and efficacy of Dupixent (dupilumab) in adults with recurring severe chronic rhinosinusitis with nasal polyps. The European Medicines Agency's Committee for Medicinal Products for Human Use also adopted a positive opinion for Dupixent in a third indication. read more >
News Update

Mobile Health, Telemedicine Solutions Firm Lands Five New Clients

News Update
  ()
With these new contracts, the Vancouver-based company continues to build its momentum in Texas. read more >

NCI Chooses Veterinary Biopharma as Select Manufacturing Contractor

Research Report
  ()
The contract's meaning, terms and benefits and the California firm's near-term catalysts are discussed in an H.C. Wainwright & Co. report. read more >
News Update

Biopharma Reports Positive Data from Alcoholic Hepatitis Study

News Update
  ()
These results are from the recently completed clinical trial of the firm's lead drug candidate. read more >

Alder BioPharmaceuticals Shares Surge 80% on Acquisition News

  ()
Shares of migraine treatment research firm Alder BioPharmaceuticals soared 84% after the company announced that it has agreed to be acquired by H. Lundbeck for $1.95 billion. read more >
News Update

Healthcare Company Rolls Out Patient App Access to Electronic Medical Records System

News Update
  ()
This is one way the Canadian firm is providing convenient, patient-centric service. read more >

Fibrocell Science Shares Rise 60% on Acquisition News

  ()
Fibrocell Science's shares traded up 60% after the company announced that it agreed to be acquired by Castle Creek Holdings for $63.3 million, or $3.00 per share. read more >

Moderna Shares Rise on the Release of Positive Results from Two mRNA Phase 1 Programs

  ()
Shares of Moderna Inc. traded up double-digits as the firm announced results from its Phase 1 CMV Vaccine Study as well as its Phase 1 data for mRNA-1944 encoding for antibody against the chikungunya virus. read more >

T2 Biosystems Receives BARDA Contract to Fight Antimicrobial Resistance, Shares Up More than 88%

  ()
This healthcare diagnostics stock rose more than 88% on Wednesday following the award of a BARDA contract that could be worth up to $69 million. read more >

Biopharma Makes Licensing Deal for Therapeutic Rights in Japan

Research Report
  ()
The company's reasons for the transaction and expected short-term, stock-moving events are provided in a ROTH Capital Partners report. read more >

Expert Investing Ideas

"DRRX earned a $10M milestone payment from Gilead."

–Ed Arce, H.C. Wainwright & Co.


"The market for DRRX's POSIMIR could be substantial."

–Brian Marckx, Zacks Small-Cap Research


"DRRX's current valuation is an interesting buying opportunity."

–Francois Brisebois, Laidlaw & Company


Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe
NASDAQ Biotech ARCA Pharmaceutical

Sanofi Pays Lexicon Pharma $260 Million to Settle Diabetes Drug Dispute

  ()
Lexicon Pharmaceuticals shares traded higher by more than 30% after the company announced termination of its alliance with Sanofi SA and a $260 million settlement over its diabetes drug Zynquista. read more >
News Update

Company Develops Cannabinoid-Measuring Process for Liquids

News Update
  ()
This proprietary method ensures the firm meets the requirements for its cannabis-containing beverages and oils. read more >

Mallinckrodt Shares Up 60% as It Announces Sale of Unit

  ()
Shares of Mallinckrodt Plc traded more than 60% higher on news that the company is selling its CDMO subsidiary BioVectra Inc. to H.I.G. Capital for $250 million. read more >
News Update

Technology License Triggers $10 Million Milestone Payment for Biopharma

News Update
  ()
This is the first of many such potential payments under the related agreement. read more >